ABSTRACT Electrophysiologic effects of 50 mg iv ajmaline were evaluated in 10 Circulation 70, No. 5, 876-883, 1984. AJMALINE, an alkaloid derived from the Indian plant Rauwolfia serpentina, has been found useful in experimental and clinical atrial and ventricular arrhythmias.1-3 By virtue of its strong depressant action on accessory pathways, the drug has been extremely successful in management of arrhythmias associated with Wolff-Parkinson-White syndrome.4 5 No information is available concerning the efficacy of ajmaline in patients with paroxysmal supraventricular tachycardia (PSVT) that is mediated by dual atrioventricular nodal pathways. The present study was designed to evaluate the elfects of ajmaline on termination and reinduction
AJMALINE, an alkaloid derived from the Indian plant Rauwolfia serpentina, has been found useful in experimental and clinical atrial and ventricular arrhythmias.1-3 By virtue of its strong depressant action on accessory pathways, the drug has been extremely successful in management of arrhythmias associated with Wolff-Parkinson-White syndrome.4 5 No information is available concerning the efficacy of ajmaline in patients with paroxysmal supraventricular tachycardia (PSVT) that is mediated by dual atrioventricular nodal pathways. The present study was designed to evaluate the elfects of ajmaline on termination and reinduction 
Subjects and methods
Ten patients, one man and nine women from 18 to 60 years old (mean 45.4 ± 13), comprised the study group and were selected on the following criteria: (1) history of electrocardiographically documented recurrent PSVT, (2) absence of preexcitation during sinus rhythm on all available electrocardiograms, and (3) electrophysiologic documentation of atrioventricular nodal reentry during PSVT. All patients were free of organic heart disease. Two patients (Nos. 2 and 10) had incomplete right bundle branch block; all others had normal 12-lead electrocardiograms.
Electrophysiologic studies were performed in patients in the postabsorptive nonsedated state. All cardioactive drug therapy was stopped a week before the study. Informed written consent was obtained from all.
THERAPY AND PREVENTION-ARRHYTHMIA ventricular apex of each subject. Multiple surface and intracardiac electrograms were recorded on a VR-12 photographic recorder (Electronics for Medicine) or on a Mingograf 8-channel ink-jet recorder (Siemens Elema) at paper speeds of 100 and 50 mm/sec. Stimuli 2 msec in duration and approximately twice diastolic threshold were delivered by a programmable stimulator (Digitimer arrhythmia investigating system, Neurolog 4279). Conduction intervals and refractory periods were measured as defined by Wu et al.7 The study protocol included: (1) incremental ventricular pacing to a paced cycle length producing ventriculoatrial block, (2) programmed ventricular extrastimulation at decreasing coupling intervals at a driven cycle length shorter than the sinus cycle length, (3) incremental atrial pacing to a paced cycle length producing AH block, (4) programmed atrial extrastimulus testing at decreasing coupling intervals during one or more atrial paced cycle lengths, (5) induction of PSVT by rapid atrial pacing, atrial extrastimulation, or rapid ventricular pacing, and delineation of the limbs of the reentrant circuit by analysis of mode of initiation of PSVT, antegrade and retrograde conduction times, and sequence of retrograde atrial activation, and (6) ventricular programmed extrastimulation during PSVT. In one patient (No. 4) intravenous atropine was required to induce sustained PSVT.
After the verification of the participation of the dual atrioventricular nodal pathway in PSVT, 50 mg of ajmaline was injected intravenously over a period of 30 sec. Blood pressure was closely monitored by cuff. Intracardiac and surface electrograms were continuously recorded at a paper speed of 100 (eight patients) or 50 mm/sec (two patients) from the beginning of the injection to allow study of the mode of break of PSVT. The last 10 cycles preceding the break were analyzed in detail to identify electrophysiologic events leading to termination of the tachycardia.
After break of PSVT was achieved, atrial and ventricular pacing and extrastimulus studies were repeated in the same sequence described earlier and an attempt was made to reinduce PSVT. Driving cycle lengths during extrastimulus testing were kept identical before and after the drug. All postdrug studies were completed within 25 min after administration of ajmaline.
Diagnosis of atrioventricular nodal reentrant tachycardia was made as previously described.6' 8 9 Since this is mainly a diagnosis made by exclusion of other causes, care was taken to exclude patients in whom there was participation of concealed accessory pathways during tachycardia.9 Specifically, in all of the 10 patients atrial activation occurred either simultaneously with or slightly before the onset of ventricular activation during the tachycardia, suggesting that the ventricle was not an essential component of the reentry circuit. '°S tatistical analysis was done with Student's t test for paired data. All results are expressed as mean ± SD.
Results
No untoward effects were observed after administration of ajmaline.
Control sinus cycle length ranged from 490 to 930 msec (mean 636 ± 150), AH figure 1) , and by the lack of a His potential after an atrial response (AH block) in one (No. 1). In patient No. 10, before break of atrioventricular nodal reentry a second short run of atrial tachycardia was initiated by a spontaneous occurrence of a premature atrial impulse and thus resulted in an increase in atrial rate. As the atrial impulse conducted down the atrioventricular node to capture the ventricle, atrioventricular nodal reentry was terminated.
Cycle length responses before termination of PSVT.
After ajmaline cycle length of the PSVT was significantly prolonged, from 289 ± 44 msec at control to 373.5 ± 60 msec (range 263 to 464; p < .01), as a result of AH and HA prolongation (table 1). The AH interval increased from 250.5 + 44 to 323 ± 57 msec (p < .01) and the HA interval from 38.5 ± 5.8 to 50.5 ± 6.4 msec (p < .001) after ajmaline. Compared with control the mean increase in AH interval of 31 ± 27% was not significantly different from the mean increase in HA interval of 32.4 ± 15.8%. In individual patients, however, the relative increase in antegrade conduction time (range 3.8% to 89%) and retrograde conduction time (range 12.5% to 66.6%) was quite variable and did not correlate with the mode of termination of tachycardia, which was blockade of retrograde pathway in most cases. Alternation in cycle length was observed in two patients (Nos. 2 and 10). Patient 2 had both AH and HA alternans, and the AH time of the short cycles after the drug was similar to that observed at control. Termination of the tachycar- Reinduction of PSVT. In eight patients tachycardia could not be induced after ajmaline. This effect was directly related to depression of the retrograde fast pathway, as shown by the marked increase in ventricu-CONTROL lar paced cycle length producing ventriculoatrial block in all the eight and total abolition of ventriculoatrial conduction in four. In five of these patients no atrial echoes were noted despite the fact that AH intervals longer than the critical AH interval observed during control study were attained with either incremental atrial pacing or atrial extrastimulus testing. This suggests a retrograde weak link (figure 4). In two patients single atrioventricular nodal reentrant echo beats conducted to the ventricle but were not followed by a second atrial echo. In one patient (No. 8) additional effects of ajmaline on antegrade slow-pathway refractoriness also contributed to failure of induction of tachycardia (table 2) .
During the control study in all the patients the cycle length of PSVT was longer than the atrial paced cycle length that produced AH block. Each of five of the eight patients in whom PSVT could not be reinduced after ajmaline had a cycle length of PSVT (before drug) similar to or longer than the atrial paced cycle length producing AH block after the drug. These findings are consistent with the observation that after ajma-PACIN CL 280 PSVT CL 270 line the antegrade limb is not the limiting factor in the induction or sustenance of PSVT. In two patients (Nos. 7 and 10) PSVT could be reinitiated after ajmaline. The cycle length of the tachycardia increased (from 260 to 310 and 240 to 290 msec, respectively) as a result of slowing of conduction in both limbs of the circuit. In both cases the AH interval increased by 40 msec and HA interval increased by 10 msec. In patient 7 the atrial paced cycle length producing AH block remained unaffected by the drug, while retrograde conduction was not sufficiently inhibited to prevent reinduction of PSVT. Although blood levels of ajmaline were not measured in our study, it is probable that in patient 10 the initiation of PSVT was related to the short duration of action of drug. Immediately after termination of arrhythmia by ajmaline, the ventricular paced cycle length producing ventriculoatrial block increased from 240 (control) to 370 msec. PSVT was, however, initiated during atrial extrastimulus testing 15 min after administration of ajmaline. On repeat incremental ventricular pacing 1:1 retrograde conduction could be achieved up to paced cycle length of 250 msec, suggesting that the effect of drug on retrograde conduction had significantly decreased.
Discussion
In patients with reentrant PSVT drugs that increase refractoriness of one or more components of the circuit can terminate or prevent induction of tachycardia. Ajmaline terminated PSVT in all of the 10 patients in our study. Prolongation of cycle length preceded termination of PSVT in all subjects. Although conduction was depressed in both the antegrade and retrograde limbs, the magnitude of depression in the two directions was quite variable in individual patients and did not correlate with the mode of termination, which in most cases was achieved by block in retrograde pathway. This suggests that, compared with the antegrade slow pathway, the retrograde fast pathway is more vulnerable to blockade by ajmaline. This effect of ajmaline resembles those of procainamide," quinidine,'2' 11 and disopyramide,6 14 The demonstration of retrograde concealed conduction in the atrioventricular node in the four patients in whom no ventriculoatrial conduction was noted after ajmaline suggests that the atrioventricular node was the site of block. The effective refractory period of the ventriculoatrial conduction system was also increased by ajmaline. In eight patients ajmaline inhibited induction of PSVT. Although the drug had demonstrable effects on both the antegrade and retrograde limbs of the reentrant circuit, prevention of PSVT was usually the result of an inability of the retrograde limb to support a circus movement,'9 as evidenced by failure to induce atrioventricular nodal reentrant echoes or sustained PSVT despite achievement of an AH interval equivalent to or longer than the one that precipitated PSVT at control. In two patients reinduction of the PSVT could not be prevented because of less pronounced inhibition of the retrograde pathway. In both cases ajmaline failed to significantly lower the retrograde block rate. The halflife of intravenous ajmaline ranges from 3 to 8 min20 and its effect on cardiac tissue lasts for from 15 to 45 mini4,21
The efficacy of other drugs in preventing induction of atrioventricular nodal reentrant PSVT has been reported to be as follows: intravenous propranolol 41 % to 44%,12 22 intravenous ouabain 44% to 54%,12. 23 intravenous ouabain plus propranolol 58% ,2 intravenous procainamide 65%,"1 oral quinidine 78%,2 13 oral disopyramide 67%,"' and intravenous disopyramide 60%.6 Intravenous verapamil converts 80% to 100% of episodes of PSVT into sinus rhythm,24, 25 but is less effective in preventing induction of PSVT after oral administration.26 One peculiar feature observed in dual atrioventricular nodal pathways has been that drugs like procainamide,4 27 quinidine,27 and disopyramide, 14 which inhibit the accessory pathway in WolffParkinson-White syndrome, prevent atrioventricular nodal reentry by selective inhibition of the retrograde fast pathway. Ajmaline is also a strong suppressant of conduction through extranodal bypass tracts. 4 In conclusion the results of our study show that intravenous ajmaline is highly effective in terminating acute episodes of PSVT mediated by dual atrioventricular nodal pathways. Further studies of the effect of oral ajmaline on induction of tachycardia are needed to evaluate its usefulness in preventing recurrence of PSVT in patients on long-term oral therapy.
